US FDA clears CASI Pharma’s IND application for CID-103 in renal allograft antibody-mediated rejection

CASI Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with organ transplant rejection and autoimmune diseases, announced FDA clearance

To access the full article, please log in or subscribe.